TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06861088: The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Sponsor: Quercis Pharma AG · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 480 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06861088 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06861088 Rescue Dossier →